Press Releases

Company News
Jan 08, 2015
PALATINE, IL -- (Marketwired) -- 01/08/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR)  today announced that the Company has entered into a Collaboration and License Agreement (the "Agreement") with Egalet US, Inc. and Egalet Ltd. (together "Egalet", subsidiaries of Egalet Corporation (NASDAQ:
Dec 23, 2014
PALATINE, IL -- (Marketwired) -- 12/23/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine hydrochloride (HCl)], Acura's next generation pseudoephedrine with methamphetamine-resistant IMPEDE
Nov 03, 2014
PALATINE, IL -- (Marketwired) -- 11/03/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2014 .
Oct 28, 2014
PALATINE, IL -- (Marketwired) -- 10/28/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the third quarter 2014 following the close of financial markets on
Oct 16, 2014
PALATINE, IL -- (Marketwired) -- 10/16/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR)  announced today that the US Food and Drug Administration (FDA) has denied on procedural grounds Acura's appeal of the position taken by Division of Anesthesia , Analgesia, and Addiction Products (DAAAP) that
Sep 29, 2014
PALATINE, IL -- (Marketwired) -- 09/29/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION® hydrocodone bitartrate with acetaminophen (AVERSION H/A) development product with the key study demonstrating
Sep 15, 2014
PALATINE, IL -- (Marketwired) -- 09/15/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has submitted a formal dispute resolution request with the FDA for Vycavert®, its abuse deterrent formulation of hydrocodone and acetaminophen tablets.
Aug 27, 2014
PALATINE, IL -- (Marketwired) -- 08/27/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has been awarded a $300,000 grant (the "Grant") by the National Institute On Drug Abuse ("NIDA") of the National Institutes of Health to fund Phase I development of Acura's new, early
Aug 15, 2014
PALATINE, IL -- (Marketwired) -- 08/15/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today preliminary discussions from a meeting held with the U.S. Food and Drug Administration (FDA) regarding the development pathway for Acura's AVERSION® hydrocodone with acetaminophen tablet
Aug 04, 2014
PALATINE, IL -- (Marketwired) -- 08/04/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2014 .
Jul 24, 2014
PALATINE, IL -- (Marketwired) -- 07/24/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the second quarter 2014 following the close of financial markets on
May 27, 2014
PALATINE, IL -- (Marketwired) -- 05/27/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the US Food and Drug Administration (FDA) advised the Company that the data from our intranasal abuse liability study AP-ADF-301 (Study 301) for our AVERSION hydrocodone bitartrate with
May 21, 2014
PALATINE, IL -- (Marketwired) -- 05/21/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement Agreement with Sandoz Inc.
May 08, 2014
PALATINE, IL -- (Marketwired) -- 05/08/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement Agreement with Ranbaxy Inc.
May 05, 2014
PALATINE, IL -- (Marketwired) -- 05/05/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first quarter ended March 31, 2014 .
Apr 28, 2014
PALATINE, IL -- (Marketwired) -- 04/28/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the first quarter 2014 following the close of financial markets on